Abstract
The purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective σ-1 receptor (S1R) PET agent <sup>18</sup>F-FTC-146. Ten healthy volunteers (5 women, 5 men) underwent whole-body PET/MRI examinations for up to 3 hours post-injection. High accumulation was observed in S1R-dense organs such as the pancreas and spleen, with moderate uptake in the brain and myocardium. The tracer was primarily cleared renally. The effective dose was calculated at 0.0259 ± 0.0034 mSv/MBq, which is within acceptable clinical limits. The study concludes that <sup>18</sup>F-FTC-146 is a safe and effective imaging agent for S1R in humans.
Introduction: The Sigma-1 Receptor Challenge
The sigma-1 receptor (S1R) is a unique "chaperone protein" found throughout the central nervous system and peripheral tissues. It plays a critical role in protein folding and ion channel modulation, making it a key player in neurodegenerative diseases (like Alzheimer’s and ALS), psychiatric disorders, and chronic pain.
To study S1R in living humans, researchers require Positron Emission Tomography (PET) tracers that are both safe and highly specific. Previous tracers often suffered from "off-target" binding—sticking to other receptors like S2R—or unfavorable pharmacokinetics. <sup>18</sup>F-FTC-146 was developed to address these issues, boasting over 1,000-fold selectivity for S1R over its closest relatives. This study represents the first-in-human evaluation to validate whether these preclinical advantages translate to clinical safety and effective imaging.
Methodology
The researchers conducted a prospective study with 10 healthy volunteers (mean age 34.3 ± 6.5 years).
- Imaging: Participants underwent simultaneous PET/MRI scans for up to 3 hours following a bolus injection of 357.2 ± 48.8 MBq of <sup>18</sup>F-FTC-146. PET/MRI was utilized to allow for excellent anatomical registration without the additional radiation dose associated with CT scans.
- Dosimetry: To calculate organ-specific radiation absorption, regions of interest (ROIs) were delineated on the scans to create time-activity curves. Internal dose assessment was performed using OLINDA/EXM software.
- Safety Monitoring: Standard vital signs were monitored continuously, and blood tests (CBC, liver, and renal panels) were performed before injection, at 24 hours, and 7 days post-injection.
Biodistribution and Target Engagement
The tracer demonstrated high accumulation in organs known for high S1R expression, such as the pancreas, spleen, and thyroid, confirming successful target engagement in humans. Moderate and sustained uptake was observed in the brain, confirming that <sup>18</sup>F-FTC-146 successfully crosses the blood-brain barrier.
Interestingly, the human brain showed no gradual "washout" of the tracer during the 3-hour window, suggesting extremely high binding affinity in humans. Furthermore, unlike some earlier tracers, <sup>18</sup>F-FTC-146 showed negligible uptake in bone, indicating the tracer is stable and does not easily defluorinate in the body.
Clearance and Dosimetry
The primary route of excretion was renal, evidenced by high uptake in the kidneys and bladder. No significant uptake was observed in the gallbladder or colon, suggesting a lack of hepatobiliary clearance.
The mean effective dose (ED) was 0.0259 ± 0.0034 mSv/MBq. For a standard 370 MBq injection, a patient would receive approximately 9.6 mSv, which is comparable to a standard <sup>18</sup>F-FDG PET scan. The urinary bladder wall received the highest absorbed dose (0.1498 mSv/MBq), which is typical for tracers with renal clearance.
Conclusion and Clinical Outlook
<sup>18</sup>F-FTC-146 was well-tolerated by all subjects with no adverse reactions reported. While the tracer showed some retention in the walls of the injection vein—a factor that future formulations may address to improve bioavailability—the overall results are highly promising.
By providing high-contrast images of S1R-dense tissues with an acceptable radiation profile, <sup>18</sup>F-FTC-146 is positioned as a valuable tool for future clinical research. Subsequent studies will focus on clinical populations, particularly those with chronic pain or neuroinflammatory conditions, to determine if S1R density changes can serve as a reliable biomarker for disease progression or treatment response.
Summary updated